Nebicapone

Nebicapone (developmental code name BIA 3-202) is a catechol O-methyltransferase (COMT) inhibitor which was under development for the treatment of Parkinson's disease but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nebicapone (developmental code name BIA 3-202) is a catechol O-methyltransferase (COMT) inhibitor which was under development for the treatment of Parkinson's disease but was never marketed. It is a nitrocatechol and is structurally related to entacapone, nitecapone, and tolcapone. The drug shows peripheral selectivity and does not significantly act in the brain.

In contrast to the centrally penetrant tolcapone, nebicapone does not potentiate the psychostimulant-like effects of amphetamine in animals. Nebicapone was found to be effective for Parkinson's disease in clinical trials. However, it also showed hepatotoxicity, including elevated liver enzymes.

As a result, its development was discontinued by 2014. Nebicapone was first described in the scientific literature by 2000.

See also

List of investigational Parkinson's disease drugs

Text derived from https://en.wikipedia.org/w/index.php?oldid=1335375068 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.